(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

FDA, FTC Warn Six Companies for Illegally Selling Copycat Food Products Containing Delta-8 THC

July 05th, 2023

Silver Spring, MD / CRWE PRESS RELEASE / July 05, 2023 -   Today, the U.S. Food and Drug Administration and the Federal Trade Commission issued warning letters to six companies for illegally selling copycat food products containing Delta-8 . Read more

Buy-Rated: AMPX, RIVN, FDMT, CBAY, HTZ, PED - Unlocking Upside Potential

July 05th, 2023

Amprius Technologies, Inc. (NYSE: AMPX), a leading provider of advanced lithium-ion battery technology, was assumed by EF Hutton with a Buy rating and a price target of $14. With $AMPX closing at $6.98 on Monday, the assigned price target suggests. Read more

Wolfspeed: $2B Deposit Fuels Momentum; Citigroup: Transocean, Valaris are a Buy

July 05th, 2023

Shares of Wolfspeed, Inc. (NYSE: WOLF) experienced a significant surge of over 10% in pre-market trading following the announcement of a wafer supply agreement and a substantial $2 billion deposit by Renesas Electronics Corporation. This agreement se. Read more

Market Buzz: Nikola's Romeo Power Assets Transfer, Impel Pharma's Patent Win

July 05th, 2023

Romeo Power, Inc., a subsidiary of Nikola Corporation (Nasdaq: NKLA), transferred ownership of its tangible and intangible assets to SG Service Co., LLC, acting as Assignee for the Benefit of Creditors of Romeo, as per a regulatory filing with the SE. Read more

Health Canada OKs Dexcom G7; HC Wainwright Bullish on Ensysce, LifeMD, Genfit

July 04th, 2023

Dexcom, Inc. (Nasdaq: DXCM) received approval from Health Canada for the Dexcom G7 Continuous Glucose Monitoring System for all types of diabetes, ages two and older. This technology can help manage diabetes more effectively and has been shown to red. Read more

Breaking Ground: Amazon's Rivian EDV to Hit the Roads of Europe

July 04th, 2023

In the coming weeks, Amazon.com, Inc. (Nasdaq: AMZN) will launch its custom electric delivery vans from Rivian in Europe, starting with Germany. Over 300 electric vans will join the existing fleet of thousands, including more than 1,000 in Germany. A. Read more

Commission Order Vacates ALJ Initial Decision and Dismisses Complaint in Case Against Altria and Juul

July 03rd, 2023

Order Clarifies Points of Law in ALJ Initial Decision Washington D.C. / CRWE PRESS RELEASE / July 3, 2023 -  On Friday, June 30, 2023, the Federal Trade Commission vacated the Administrative Law Judge’s (ALJ) initial decision&. Read more

Malibu Boats OKs $100M Settlement in Product-Liability Case

July 03rd, 2023

Malibu Boats, Inc. (Nasdaq: MBUU) previously disclosed that it and its subsidiary, Malibu Boats, LLC, were defendants in two product liability cases (the Batchelder Matters).  These cases involve a personal injury accident from 2014, which oc. Read more

Q2 Delivery Figures Propel Rivian; Arrival's Merger Deal Terminates

July 03rd, 2023

Shares of Rivian Automotive, Inc. (Nasdaq: RIVN) experienced a significant surge of over 17% following the release of its better-than-expected Q2 delivery figures. During the second quarter of 2023, Rivian produced a total of 13,992 vehicles and d. Read more

Amneal Pharma Faces Parkinson's Candidate Setback with FDA's CRL

July 03rd, 2023

Shares of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) dropped over 10% in after-hours trading due to a Complete Response Letter from the FDA regarding the company's New Drug Application for IPX203 to treat Parkinson's disease, a neurological condition . Read more